BUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨

路透中文

Oct 21, 2025

BUZZ-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨

10月21日 - ** 药物开发商Hoth Therapeutics HOTH.O股价盘前上涨14.4%至1.59美元

** 公司称其实验性药物HT-KIT已获得美国FDA颁发的 "孤儿药 "标签，用于治疗系统性肥大细胞增多症和胃肠道间质瘤

** 美国 FDA 授予该公司孤儿药资格，以促进治疗影响美国少于 20 万人的罕见疾病的药物开发。

** 截至上次收盘，股价累计上涨 85.8

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577878875"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577878875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577878875?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-21 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577878875","market":"us","top_or_hot":-1,"title":"BUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨</title></head><body><p><span>10月21日</span><span> - </span>** 药物开发商Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>HOTH.O</span>股价盘前上涨14.4%至1.59美元 </p><p>** 公司称其实验性药物HT-KIT已获得美国FDA颁发的 \"孤儿药 \"标签，用于治疗系统性肥大细胞增多症和胃肠道间质瘤</p><p>** 美国 FDA 授予该公司孤儿药资格，以促进治疗影响美国少于 20 万人的罕见疾病的药物开发。</p><p>** 截至上次收盘，股价累计上涨 85.8</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-21 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨</title></head><body><p><span>10月21日</span><span> - </span>** 药物开发商Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>HOTH.O</span>股价盘前上涨14.4%至1.59美元 </p><p>** 公司称其实验性药物HT-KIT已获得美国FDA颁发的 \"孤儿药 \"标签，用于治疗系统性肥大细胞增多症和胃肠道间质瘤</p><p>** 美国 FDA 授予该公司孤儿药资格，以促进治疗影响美国少于 20 万人的罕见疾病的药物开发。</p><p>** 截至上次收盘，股价累计上涨 85.8</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nL4S3W20WH:1","article_id":"2577878875","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577878875","pubTimestamp":1761050001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨10月21日 - ** 药物开发商Hoth Therapeutics HOTH.O股价盘前上涨14.4%至1.59美元 ** 公司称其实验性药物HT-KIT已获得美国FDA颁发的 \"孤儿药 \"标签，用于治疗系统性肥大细胞增多症和胃肠道间质瘤** 美国 FDA 授予该公司孤儿药资格，以促进治疗影响美国少于 20 万人的罕见疾病的药物开发。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"BUZZ-Hoth Therapeutics Rises After Rare Oncology Drug Gets FDA Orphan Drug Label","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"BUZZ-Hoth Therapeutics 在罕见肿瘤药物获得 FDA 孤儿药标签后股价上涨10月21日 - ** 药物开发商Hoth Therapeutics HOTH.O股价盘前上涨14.4%至1.59美元 ** 公司称其实验性药物HT-KIT已获得美国FDA颁发的 \"孤儿药 \"标签，用于治疗系统性肥大细胞增多症和胃肠道间质瘤** 美国 FDA 授予该公司孤儿药资格，以促进治疗影响美国少于 20 万人的罕见疾病的药物开发。** 截至上次收盘，股价累计上涨 85.8(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}